Richard A.  Gonzalez net worth and biography

Richard Gonzalez Biography and Net Worth

CEO of AbbVie
Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 48,000 people worldwide and markets medicines in more than 175 countries. 

Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada. 

Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.

What is Richard A. Gonzalez's net worth?

The estimated net worth of Richard A. Gonzalez is at least $87.51 million as of February 28th, 2024. Mr. Gonzalez owns 519,099 shares of AbbVie stock worth more than $87,514,900 as of June 15th. This net worth evaluation does not reflect any other investments that Mr. Gonzalez may own. Additionally, Mr. Gonzalez receives a salary of $7,190,000.00 as CEO at AbbVie. Learn More about Richard A. Gonzalez's net worth.

How old is Richard A. Gonzalez?

Mr. Gonzalez is currently 70 years old. There are 7 older executives and no younger executives at AbbVie. Learn More on Richard A. Gonzalez's age.

What is Richard A. Gonzalez's salary?

As the CEO of AbbVie Inc., Mr. Gonzalez earns $7,190,000.00 per year. Learn More on Richard A. Gonzalez's salary.

How do I contact Richard A. Gonzalez?

The corporate mailing address for Mr. Gonzalez and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Richard A. Gonzalez's contact information.

Has Richard A. Gonzalez been buying or selling shares of AbbVie?

Richard A. Gonzalez has not been actively trading shares of AbbVie during the past quarter. Most recently, Richard A. Gonzalez sold 138,616 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $177.27, for a transaction totalling $24,572,458.32. Following the completion of the sale, the chief executive officer now directly owns 519,099 shares of the company's stock, valued at $92,020,679.73. Learn More on Richard A. Gonzalez's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Richard A. Gonzalez Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2024Sell138,616$177.27$24,572,458.32519,099View SEC Filing Icon  
7/31/2023Sell18,500$149.15$2,759,275.00625,294View SEC Filing Icon  
12/9/2021Sell174,100$123.23$21,454,343.00View SEC Filing Icon  
3/1/2021Sell170,113$108.61$18,475,972.93450,981View SEC Filing Icon  
12/11/2018Sell16,850$88.75$1,495,437.50286,203View SEC Filing Icon  
2/28/2018Sell8,280$117.88$976,046.40321,292View SEC Filing Icon  
11/21/2017Sell218,193$94.01$20,512,323.93492,030View SEC Filing Icon  
8/7/2017Sell193,131$71.00$13,712,301.00469,623View SEC Filing Icon  
8/4/2017Sell87,899$71.02$6,242,586.98342,353View SEC Filing Icon  
8/3/2017Sell65,861$71.00$4,676,131.00342,353View SEC Filing Icon  
5/19/2017Sell71,235$65.49$4,665,180.15349,462View SEC Filing Icon  
3/8/2017Sell72,016$64.25$4,627,028.00369,113View SEC Filing Icon  
6/2/2016Sell285,953$63.82$18,249,520.46624,374View SEC Filing Icon  
5/11/2016Sell39,000$63.80$2,488,200.00338,421View SEC Filing Icon  
4/28/2015Sell102,964$64.67$6,658,681.88View SEC Filing Icon  
See Full Table

Richard A. Gonzalez Buying and Selling Activity at AbbVie

This chart shows Richard A Gonzalez's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89


4,377,638 shs

Average Volume

4,854,812 shs

Market Capitalization

$297.71 billion

P/E Ratio


Dividend Yield